Cardinal health investor day to highlight long-term value creation

Narrowing fiscal year 2023 non-gaap diluted eps guidance to $5.65 to $5.80, from $5.60 to $5.80 (13% growth at the mid-point)1 providing preliminary fiscal year 2024 non-gaap diluted eps guidance of $6.45 to $6.70 (15% growth at the mid-points) providing long-term financial targets reflecting 12% to 14% growth of non-gaap diluted eps (3-year cagr)2 raising long-term financial target for pharmaceutical segment profit to 4% to 6% growth, from "low-single digit to mid-single digit" growth updating medical improvement plan timeline for $650m+ in segment profit to fy263 board of directors approved new $3.5b share repurchase authorization expiring december 31, 2027; company plans to execute at least $2.0b of share repurchases over the next three years company provides strategic updates dublin, ohio , june 8, 2023 /prnewswire/ -- cardinal health (nyse: cah) today will host an investor day beginning at 9:00 a.m. et, where among other updates, management will detail its growth strategies to maximize the company's potential for all stakeholders and move healthcare forward.
CAH Ratings Summary
CAH Quant Ranking